OncoCyte Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Josh Riggs

Amministratore delegato

US$514.1k

Compenso totale

Percentuale dello stipendio del CEO	47.1%
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	2.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Josh Riggs rispetto agli utili di OncoCyte?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$514k	US$242k	-US$19m

Compensazione vs Mercato: La retribuzione totale di Josh ($USD 514.11K ) è circa la media per le aziende di dimensioni simili nel mercato German ($USD 475.63K ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Josh con le performance aziendali.

AMMINISTRATORE DELEGATO

Josh Riggs (40 yo)

less than a year

Mandato

US$514,110

Compensazione

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Joshua Riggs	President	less than a year	US$514.11k	Nessun dato
James Liu	Senior Director	1.1yrs	US$259.74k	0% € 0
Ekkehard Schutz	Chief Science Officer	less than a year	Nessun dato	Nessun dato
Yuh-Min Chiang	Senior Vice President of R&D and Product Development	no data	Nessun dato	Nessun dato
Sandra O'Donald	Senior Vice President of Business Operations	less than a year	Nessun dato	Nessun dato
Michael West	Scientific Advisor	8yrs	US$328.84k	Nessun dato
Peter Hong	Secretary	no data	Nessun dato	Nessun dato
Sara Riordan	Director of Medical Education	no data	Nessun dato	Nessun dato

0.8yrs

Durata media

40yo

Età media

Gestione esperta: Il team dirigenziale di 7OC0 non è considerato esperto (durata media 0.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Joshua Riggs	President	less than a year	US$514.11k	Nessun dato
Louis Silverman	Lead Independent Director	less than a year	US$17.30k	0.000040% € 8.6
Andrew Arno	Independent Chairman	8.3yrs	US$125.01k	0.59% € 127.1k
Alfred Kingsley	Independent Director	14.1yrs	US$118.50k	0.28% € 59.8k
Daniel Hayes	Member of Scientific & Medical Advisory Board	2.8yrs	Nessun dato	Nessun dato
David R. Gandara	Member of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
Robert Ferris	Member of Scientific & Medical Advisory Board	no data	Nessun dato	Nessun dato
John Kirkwood	Member of Scientific & Medical Advisory Board	2.8yrs	Nessun dato	Nessun dato
Andrew Last	Independent Director	7.8yrs	US$118.00k	0.037% € 7.8k
Fred Hirsch	Member of Scientific & Medical Advisory Board	2.8yrs	Nessun dato	Nessun dato
Heinz-Josef Lenz	Member of Scientific & Medical Advisory Board	2.8yrs	Nessun dato	Nessun dato
Ignacio Wistuba	Member of Scientific & Medical Advisory Board	2.8yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 7OC0 non è considerato esperto (durata media del mandato 2.8 anni), il che suggerisce un nuovo consiglio.

OncoCyte Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

Oncocyte Corporation Announces Executive Changes

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Corporation Announces Executive Changes

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Third quarter 2022 earnings released: US$0.081 loss per share (vs US$0.15 loss in 3Q 2021)

High number of new directors

Third quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 3Q 2021)

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought €142k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.12 loss in 2Q 2021)

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.048 loss in 1Q 2021)

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

High number of new directors

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

Forecast to breakeven in 2024

First quarter 2021 earnings released: US$0.048 loss per share (vs US$0.13 loss in 1Q 2020)

CEO, President & Director recently bought €44k worth of stock

OncoCyte Corporation Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

Oncocyte Corporation Announces Formation of Medical Advisory Board

Oncocyte Corporation Announces Agreement with MultiPlan Network, Expanding Patient Access to Determarx™

OncoCyte Corporation to Report Q4, 2020 Results on Mar 16, 2021